MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ecco-jcc/jjaf025

Медицинская библиотека · Journal of Crohn's & colitis · 2025

Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis.

Reinisch Walter, Loftus Edward V, Schreiber Stefan, Rubin David T, Louis Edouard, Hecht Patrick M, Barrachina Elena Marced, Kalabic Jasmina, Vladea Ramona, Sharma Dolly, Duan Weijiang Rachel, Zhang Yafei, Panaccione Remo

СтатьяРандомизированное исследованиеКлиническое исследование III фазыПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: This post hoc analysis evaluated the corticosteroid-sparing effects of risankizumab (RZB) therapy in patients with moderate-to-severe ulcerative colitis in the phase 3 induction and maintenance studies, INSPIRE and COMMAND.

METHODS

Patients were randomized (2:1) to 12 weeks of intravenous RZB or placebo (PBO) induction therapy; responders to intravenous RZB were randomized (1:1:1) to receive subcutaneous RZB 180 mg, 360 mg, or PBO (RZB withdrawal) maintenance therapy. Baseline corticosteroid doses were maintained during induction, with a mandatory taper beginning at maintenance week 0. Efficacy outcomes were evaluated by baseline corticosteroid use at induction week 12, while corticosteroid-free clinical and endoscopic outcomes were assessed at maintenance week 52 among the overall population and among patients on corticosteroids at baseline. Safety was also assessed.

RESULTS

At baseline, 35.7% (348/975) of patients were taking corticosteroids. At induction week 12, greater rates were observed for clinical, endoscopic, and patient-reported outcomes in RZB 1200 mg-treated patients compared with PBO, regardless of baseline corticosteroid use. RZB 180 mg and 360 mg treatment resulted in higher corticosteroid discontinuation rates (RZB 180 mg 64.9% [48/74]; RZB 360 mg 54.2% [32/59]; PBO [withdrawal] 36.8% [25/68], P ≤ .01) and corticosteroid-free clinical, endoscopic, and patient-reported outcomes at week 52, compared with PBO (withdrawal). The rates of treatment-emergent adverse events were similar regardless of baseline corticosteroid use during induction and maintenance.

CONCLUSIONS

The efficacy of RZB induction therapy was independent of corticosteroid use, with high rates of corticosteroid-free outcomes observed in the overall population and among patients with baseline corticosteroid use, reaffirming the potential of RZB to serve as a corticosteroid-sparing therapy for patients with ulcerative colitis.

CLINICALTRIAL.GOV NUMBERS: NCT03398148 and NCT03398135.

Для цитирования: Reinisch Walter, Loftus Edward V, Schreiber Stefan, Rubin David T, Louis Edouard, Hecht Patrick M, Barrachina Elena Marced, Kalabic Jasmina, Vladea Ramona, Sharma Dolly, Duan Weijiang Rachel, Zhang Yafei, Panaccione Remo. Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis.. Journal of Crohn's & colitis. 2025. DOI: 10.1093/ecco-jcc/jjaf025.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.